Successes Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications

Department of Nephrology, Monash Medical Center, Clayton, Victoria, Australia.
The AAPS Journal (Impact Factor: 3.8). 03/2010; 12(3):243-53. DOI: 10.1208/s12248-010-9182-4
Source: PubMed


Biomarkers are important tools for identifying and stratifying diseases, predicting their progression and determining the effectiveness, safety, and doses of therapeutic interventions. This is important for common chronic diseases such as diabetic nephropathy, osteoporosis, and rheumatoid arthritis which affect large numbers of patients worldwide. This article summarizes the current knowledge of established and novel biomarkers for each of these diseases as presented at the 2008 AAPS/ACCP joint symposium "Success Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications," in Atlanta, Georgia. The advantages and disadvantages of various proteomic, metabolomic, genomic, and imaging biomarkers are discussed in relation to disease diagnosis and stratification, prognosis, drug development, and potential clinical applications. The use of biomarkers as a means to determine therapeutic interventions is also considered. In addition, we show that biomarkers may be useful for adapting therapies for individual needs by allowing the selection of patients who are most likely to respond or react adversely to a particular treatment. They may also be used to determine whether the development of a novel therapy is worth pursuing by informing crucial go/no go decisions around safety and efficacy. Indeed, regulatory bodies now suggest that effective integration of biomarkers into clinical drug development programs is likely to promote the development of novel therapeutics and more personalized medicine.

Download full-text


Available from: Shashi Amur, Oct 06, 2015
8 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Cretaceous sedimentary basins in Mongolia are grouped into three major depositional provinces (Altai, Khangai-Khentei and Gobi) with ten basins (basins of Great Lakes, Valley of Lakes, Arkhangai, Onon, Choir-Nyalga, Choibalsan, Transaltai Gobi, Umnogobi, Dornogobi and Tamsag), which are all filled by continental deposits with abundant vertebrate and invertebrate fossils as well as plant remains. Most of their stratigraphical, paleontological and sedimentological features are summarized, giving regional corelation of the strata and taking account of environmental characteristics.
    Developments in Palaeontology and Stratigraphy DOI:10.1016/S0920-5446(00)80024-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent results indicate that prothymosin alpha (ProT alpha) may be useful in designing future therapeutic interventions in cancer patients and in potentiating the immune system. We described recently the presence and characteristics of two binding sites for ProT alpha on human peripheral blood mononuclear cells (PBMC). In search of a receptor upregulation, we decided to corroborate this finding on two lymphocytic populations, (PHA-activated) lymphoblasts and YT cells. The kinetics of [I-125]ProT alpha binding to lymphoblasts were fast at room temperature but with YT cells were slower, Analysis of steady-state binding data identified two binding sites in lymphoblasts with an apparent equilibrium K-d of 44-75 pM and 4228-9143 sites per cell for the high-affinity receptor and 1.7-2.9 nM and 20,534-35,044 sites per cell for the low-affinity receptor. However, it identified only one site with a K-d of 265-435 pM and 8318-27,237 sites per cell in YT cells, We conclude that exists a ProT alpha receptor in the CD3(+) T cell population, and this presence is regulated, After binding to cell surface, [I-125]ProT alpha is internalized in a short period of time and then degraded; therefore, we conclude that the dynamics of ProT alpha receptor turnover in part determines the concentration of ProT alpha available to induce its enhancing effects.
    Journal of Interferon & Cytokine Research 08/1995; 15(8):731-737. DOI:10.1089/jir.1995.15.731 · 2.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prothymosin alpha (ProTalpha) is a highly acidic and small protein of only 111 amino acids with an unusual primary structure. One would expected it to play an essential role in the organism, as it has a wide distribution and is high conserved among mammals, yet its exact function remains elusive. Despite the number of effects described for ProTalpha, intracellular and extracellular, none are accepted as its physiological role. Furthermore, many other aspects of its biology still remain obscure. In this review, we discuss the structural properties, location, gene family, functions and immunomodulatory activities of and cellular receptors for ProTalpha. These topics are addressed in an attempt to reconcile opposing outlooks while emphasizing those points where scant investigations do exist. We have also re-evaluated some previous results in light of the structural properties of ProTalpha and have found that molecular mimetism could be the underlying basis. This molecular mimicry hypothesis provides a clue that must not be overlooked for a realistic appraisal of future results.
    Peptides 10/2000; 21(9):1433-46. DOI:10.1016/S0196-9781(00)00288-6 · 2.62 Impact Factor
Show more